February 4, 2023, Nanjing Zenshine Pharmaceuticals Co., Ltd (Zenshine Pharma) announced that the first patient was dosed in a phase 3 clinical trial (CTR20221729) of ZX-7101A, a novel PA inhibitor for the treatment of uncomplicated Influenza. This multicenter，randomized, double-blind, placebo-controlled phase3 study aims to confirm the efficacy and safety of ZX-7101A in patients with uncomplicated Influenza. 

ZX-7101A is a novel PA inhibitor developed by Zenshine Pharma. It has broad-spectrum activity against influenza A, B and highly lethal variants of influenza viruses. In comparison with Baloxavir, ZX-7101A showed greater efficacy in animal model and improved bioavailability. In the phase 1 clinical trial, ZX-7101A showed excellent safety profile and optimal pharmacokinetic properties. 

Zenshine Pharma is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients. Zenshine Pharma leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine Pharma commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics.